Details for Patent: 8,685,998
✉ Email this page to a colleague
Which drugs does patent 8,685,998 protect, and when does it expire?
Patent 8,685,998 protects ENVARSUS XR and is included in one NDA.
This patent has thirty patent family members in sixteen countries.
Summary for Patent: 8,685,998
Title: | Tacrolimus for improved treatment of transplant patients |
Abstract: | An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form. |
Inventor(s): | Gordon; Robert D. (Sandy Springs, GA), Holm; Per (Vanlose, DK), Lademann; Anne-Marie (Klampenborg, DK), Norling; Tomas (Lyngby, DK) |
Assignee: | Veloxis Pharmaceuticals A/S (Horsholm, DK) |
Application Number: | 12/499,034 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,685,998 |
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 8,685,998
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF ORGAN REJECTION | ⤷ Try a Trial | |||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Try a Trial | |||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS | ⤷ Try a Trial | |||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF ORGAN REJECTION | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,685,998
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Denmark | 2007 00783 | May 30, 2007 |
Denmark | 2007 01573 | Nov 7, 2007 |
International Family Members for US Patent 8,685,998
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 081520 | ⤷ Try a Trial | |||
Canada | 2688381 | ⤷ Try a Trial | |||
Canada | 2729948 | ⤷ Try a Trial | |||
Denmark | 2167033 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |